Testing the Addition of M3814 (Peposertib) to Radiation Therapy for Patients With Advanced Head and Neck Cancer Who Cannot Take Cisplatin
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Eastern Cooperative Oncology Group
Emory University
Eastern Cooperative Oncology Group
NRG Oncology
Wake Forest University Health Sciences
Cancer Research UK
UNC Lineberger Comprehensive Cancer Center
Memorial Sloan Kettering Cancer Center
Mayo Clinic
Emory University
Ohio State University Comprehensive Cancer Center
National Medical Research Radiological Centre of the Ministry of Health of Russia
Brigham and Women's Hospital
National Cancer Institute (NCI)
Lithuanian University of Health Sciences
NRG Oncology
University of California, San Diego
M.D. Anderson Cancer Center
Medical University of South Carolina
H. Lee Moffitt Cancer Center and Research Institute
Sir Mortimer B. Davis - Jewish General Hospital
University of Texas Southwestern Medical Center
Cancer Research UK
Mansoura University
Insel Gruppe AG, University Hospital Bern
Inhibrx Biosciences, Inc
University of Connecticut
Sanford Health
Insel Gruppe AG, University Hospital Bern
Thomas Jefferson University
Washington University School of Medicine
Fudan University
Emory University
Centre hospitalier de l'Université de Montréal (CHUM)
University of Utah
University of Miami
National Cancer Institute (NCI)
University of Wisconsin, Milwaukee
University of Wisconsin, Milwaukee
Ain Shams University
Covenant Health Cancer Center